Opinion|Videos|April 1, 2025
Management of Neurogenic Bladder
Author(s)Tamara Kaplan, MD
Panelist discusses how, for managing neurogenic bladder, neurologists should focus on individualized treatment plans emphasizing bladder emptying schedules, antimuscarinic medications when indicated, and clean intermittent catheterization as needed. Regular monitoring of renal function, urinary tract infection prevention, and coordination with urologists are crucial. Patient education about lifestyle modifications and adherence to treatment regimens is essential for optimal outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What advice do you have for neurologists about managing neurogenic bladder?
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Williams, MD, is joined by Marcus Gates, MD, and they discuss recognizing cervical nerve root and spinal cord compression, navigating treatment options, and determining when surgery may be appropriate.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.
The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.
Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.
uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy
2
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
3
PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS
4
Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162
5